Wolinetz began work in 2002 at the
Federation of American Societies for Experimental Biology where she served as the Director of Scientific Affairs and Public Relations. Her work focused on bioethical concerns, including
stem cells and
biosecurity. Wolinetz also worked as a Chair at the
Association for Women in Science She oversaw the streamlining the
institutional review board policy for multisite research and helped launch the NIH's data sharing policy. She also oversaw programs to combat sexual harassment in the scientific field. In addition, Wolinetz led the Institute's efforts to develop better practices for dealing with emerging
biotechnology. She developed regulations for
dual-use biotechnology, especially
gain-of-function research, and transformed the Recombinant DNA Advisory Committee (RAC) working on gene editing into the Novel and Exceptional Technology and Research Advisory committee (NExTRAC), which covered the broader field of novel biotechnology advances. In that role, she developed a policy to increase
biotechnology and
biomanufacturing in the United States, oversaw the President's American Pandemic Preparedness plan,
Lewis-Burke Associates In 2023, Wolinetz joined Lewis-Burke Associates to work as the Principal and Chair for their Health and Bioscience Innovation Policy Practice Group. == References ==